Agilent Dr. Oligo Pro II PMA

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Centers for Disease Control and Prevention (CDC) The Biotechnology Core Facility Branch (BCFB) within the Division of Core Laboratory and Scientific Resources (DCLSR) intends to award a firm fixed price purchase order to Agilent Technoligies Inc. 2850 Centerville RD Wilmington, Delaware 19808. Under the authority of FAR 13.106-1(b)(1)(i), only one responsible source and no other supplies or services will satisfy agency requirements. The purpose of this procurement is procure a service agreement with Agilent for preventative maintenance on the Oligo Pro II.

The contractor shall provide annual preventative maintenance services on the following system

Agilent Oligo Pro II system

21033_1 /MY21201018

SECTION 4 – TASKS TO BE PERFORMED

1. Provide annual equipment maintenance of Agilent Oligo pro II System.


2. Provide all labor, travel, and parts with unlimited breakdown calls included


3. Provide one scheduled preventative maintenance visit per year which includes a full system diagnostic using software and critical parts exchanged


4. Provide priority response for all breakdown calls within 24 to 48 hours

The instrument that is part of the service contract has many proprietary parts manufactured and sold exclusive by the proposed vendor, Agilent technologies. Only Agilent service engineers have access to all the training and parts needed to maintain the instruments at the required service levels.

The anticipated award date of this action is on or before July 01, 2026. The applicable NAICS code is 811210 Electronic and Precision Equipment Repair and Maintenance. This notice of intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the warranties and proof as being an authorized distributor of the product. Capability statements shall not exceed 2 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order. Capability statements are due by 3:00 PM Eastern Standard Time (EST), June 22, 2026. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to Javier Aponte email address at: zsm9@cdc.gov NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.